Background {#Sec1}
==========

Stroke is the second most common cause of death and the third most common cause of disability-adjusted life-years (DALYs) worldwide in 2010 \[[@CR1],[@CR2]\]. Incidence rates, 30-day case-fatality data, stroke survival rates and recurrence risks are useful epidemiological data which help to understand how well our primary prevention, quality of hospital care and secondary prevention have been conducted \[[@CR3]\]. The overall burden of disease data from the World Health Organization shows stroke is still in the top 6 based on disability adjusted life-years \[[@CR4]\]. Therefore, a comprehensive secondary prevention campaign should target the prevention of stroke recurrence, vascular dementia and death \[[@CR5],[@CR6]\].

Recurrence and survival rates are useful data to compare the natural history of a disease against the effect of therapeutic interventions. In community-based studies which included all major stroke types together, the 3-year cumulative risk of recurrent stroke has been reported to be varied from 6 to 25% \[[@CR7]-[@CR10]\]. The reported cumulative risk of death in population-based studies which included all stroke types ranged across the last three decades in high and middle-income countries. In the 1980s in the UK, the 1-year risk was 31% and the 5-year risk was 50% \[[@CR7]\]. In the 1990s, in Australia, the 1-year risk was 38% and the 5-year risk was 60%; \[[@CR8]\]. In the 2000s, in Belarus, the 1-year risk was 38% and the 5-year risk was 59% \[[@CR11]\]. As far as we know, no prospective population-based study has been conducted in a South American country, where the stroke burden is huge.

As we had shown that the incidence of stroke, 30-day case-fatality and mortality had fallen by a third in Joinville, Southern Brazil in the last decade \[[@CR12]\] (1995 to 2005), we now aimed to know the stroke recurrence behavior in our population. Therefore, we conducted a prospective community-based study of a cohort of patients after their first-ever stroke to determine the 3-year survival rates, levels of recurrence and the major causes of death in Joinville, Brazil.

Methods {#Sec2}
=======

Study design and population {#Sec3}
---------------------------

This is a population-based prospective cohort study. Using the Joinville Stroke Registry, an ongoing population-based registry was established in 2005. We ascertained all the cases of first-ever stroke occurring among patients living in Joinville city, Southern Brazil, between October 1, 2009, and September 30, 2010. This cohort was then followed up until September 30, 2013. On the basis of intercensus data, the estimated population of the study area was 509,743 inhabitants who lived in area of 1130 km \[[@CR2],[@CR13]\]. Joinville city has four hospitals, three intermediate care units and one public institutional care facility. All the hospitals have computed tomography (CT) services available on a 24-hour basis. Two thirds of the city population uses only the public health system, which consists of nine state-run health districts with 56 primary care facilities.

Baseline assessment {#Sec4}
-------------------

The cohort methods have been described elsewhere \[[@CR12]\]. In brief, we used multiple overlapping data sets including medical records from all city hospitals, death certificates, and outpatient monitoring in the state-run and private units (WHO STEPS) \[[@CR14],[@CR15]\]. Three research nurses discussed all the stroke cases occurring in all the hospitals with a neurologist on a daily basis. On a weekly basis, a neuroradiologist unaware of patients' symptoms analyzed all brain CT scans, magnetic resonance images and digital angiographies. Every month we analyzed all death certificates (DC) issued by the Municipal Department of Health. We initially selected all death certificates containing any references to the tenth revision of the International Classification of Diseases (ICD-10) codes related to stroke (I61 through I69) or any descriptions of cerebrovascular diseases, as well as those listing the death as being from an unknown cause (R99). The deaths of patients not identified on hospitals records were investigated through the evaluation of hospital medical charts and, when available, imaging examinations. Every week the state-run health units searched their electronic records for any stroke-related diagnoses listed in the ICD-10. This happened monthly at the institutional care facility. However, not all patients identified agreed to be admitted. Such patients were offered an appointment as outpatient (1 or 2 per month, usually minor strokes or a stroke mimics). These records were reviewed and when necessary each medical chart was late discussed with a neurologist (NLC). Private city physicians received a reminder sticker with each study contact.

Stroke definition and cohort criteria {#Sec5}
-------------------------------------

Stroke was defined according to World Health Organization (WHO) definitions \[[@CR16]\]. Ischemic stroke subtypes were classified according TOAST classification \[[@CR17]\]. The primary outcomes were death or stroke recurrence. We defined recurrent stroke as new stroke event, additionally requiring a period of neurological stability of ≥24 hours between index and recurrent stroke, and the exclusion of other potential causes of neurological deterioration \[[@CR18]\]. Individuals who had suffered the second stroke event were again interviewed in order to identify the subtype of the stroke recurrence. All surviving patients were followed-up through telephone calls by a research nurse of the Joinville Stroke Registry at 1, 6, 12, 24 and 36 months after the event. They also had face-to-face meetings with their neurologist or general physician. We classified the causes of death using standardized diagnostic criteria for stroke \[[@CR16]\], recurrent stroke \[[@CR18]\], myocardial infarction and other vascular death, and nonvascular death (see definitions, below) \[[@CR19]\].

Cohort inclusion and exclusion criteria {#Sec6}
---------------------------------------

We included all the cases of residents of Joinville, regardless of age, diagnosed with any type of first-ever ischemic stroke (IS), primary intracerebral hemorrhage (PIH) or subarachnoid hemorrhage (SAH). We also included residents in the city with confirmed strokes that occurred outside the city limits. Patients experiencing a stroke for the first time who had experienced a previous transient ischemic attack (TIA), were also classified as a first-ever stroke case. We excluded TIA diagnoses, all recurrent events, and stroke patients who died in the first 24 hours of onset, as well as patients residing outside the Joinville city limits, or patients with subdural, epidural or intracerebral hemorrhage secondary to arteriovenous malformation or tumors.

Stratification types of deaths {#Sec7}
------------------------------

We classified the causes of death into the 5 groups that were used in the Oxfordshire Community Stroke Project: \[[@CR7]\] (1) deaths resulting from a first-ever stroke due to the direct effects of a brain lesion or complications of resulting immobility, including deaths from bronchopneumonia even if they occurred several years after the stroke if the stroke-related disability was thought to be contributory; (2) deaths resulting from recurrent stroke that were directly due to a brain lesion or complications of immobility; (3) deaths caused by cardiovascular events that were definitely or probably from myocardial infarction, ruptured aortic aneurysms, peripheral arterial disease, or sudden death when there was no alternative explanation; (4) deaths from nonvascular events that were not due to any stroke-related disability and included such illnesses as cancer, injuries, or suicide; and (5) deaths of undetermined cause where there was insufficient information to establish a cause.

Statistical analysis {#Sec8}
--------------------

We performed descriptive statistical analysis to compare baseline characteristics using the qui-square test, the Student *t* test, or the Mann--Whitney test according to distribution. The Kaplan-Meier product-limit technique was used to generate survival probabilities and survival curves. The risk ratio was estimated by using the Cox proportional model and the Log-Rank test to compare survival curves among stroke types. We used the R Project for Statistical Computing program version 3.1.1. The study was approved by the ethics in research committees of the Hospital Municipal São José, the Hospital Regional, the Centro Hospitalar Unimed, the Hospital Dona Helena, and the University Hospital of Joinville Region-Univille, Brazil.

Results {#Sec9}
=======

Study population {#Sec10}
----------------

We identified 727 patients with stroke from October 1, 2009 to September 30, 2010. Of those, 225 had prior strokes, 63 were TIA events, nine patients died in the first 24 hours and 23 patients moved to other cities. These 320 patients were excluded. Therefore, the final cohort sample was 407 patients, among whom 83% (336/407) suffered ischemic strokes, 11% (43/407) had primary intracerebral hemorrhages and 7% (28/407) experienced subarachnoid hemorrhages (Figure [1](#Fig1){ref-type="fig"}).Figure 1Flowchart of stroke recurrence or death over 3 years after first-ever stroke in Joinville, Brazil.

The mean age of these patients at baseline was 63 ± 16 years, with a median age of 64 years. The ischemic stroke subtypes distribution by TOAST classification were: 27% (92/336) small artery occlusion (SAO); 27% (91/336) undetermined (UND); 25% (84/336) cardioembolic (CE); 17% (57/336) large artery atherothrombotic (LAA) and 4% (12/336) other determined strokes (OD). Table [1](#Tab1){ref-type="table"} shows the baseline characteristics, premorbid medications and premorbid risk-factor prevalence among IS, PIH and SAH patients.Table 1**Premorbid cardiovascular risk factors and medications in patients with first ever ischemic stroke, primary intracerebral hemorrhage and subarachnoid hemorrhage, Joinville 2009-2010IS (n = 336)PIH (n = 43)SAH (n = 28)Baseline characteristics**Men189 (56%)19 (44%)14 (50%)Age, in years, mean (SD)63 (16)62 (16)60 (13)**Premorbid medication**Antiplatelet agent102 (30%)5 (12%)3 (11%)Anticoagulant12 (4%)2 (5%)0 (0%)Lipid lowering agent59 (18%)5 (12%)6 (21%)**Premorbid risk factor**Total cholesterolMean baseline (mg/dl)191 (46)184 (30)196 (57)Proportion ≥ 6 mmol/L45 (16%) \[[@CR1]\]2 (8%) \[[@CR2]\]2 (33%) \[[@CR3]\]Systolic blood pressureMean (SD)144 (27)166 (36)142 (25)Proportion ≥ 150 mmHg106 (39%) \[[@CR4]\]14 (56%) \[[@CR5]\]7 (32%) \[[@CR6]\]Proportion ≥ 160 mmHg80 (29%)9 (36%)3 (14%)Diastolic blood pressureMean (SD)87 (16)95 (21)88 (14)Proportion ≥ 90 mmHg69 (26%) \[[@CR7]\]10 (44%) \[[@CR8]\]6 (29%) \[[@CR9]\]Proportion ≥ 100 mmHg30 (11%)7 (30%)1 (5%)SmokingCurrent67 (20%)9 (21%)12 (43%)Ex102 (30%)14 (32%)4 (14%)Never168 (50%)20 (47%)9 (32%)Diabetes78 (23%)5 (12%)2 (8%)Atrial fibrillation38 (11%)5 (12%)0 (0%)Myocardial infarction32 (9%)2 (5%)1 (4%)IS: ischemic stroke; PIH: primary intracerebral hemorrhage; SAH: subarachnoid hemorrhage; Total cholesterol data were available in: \[[@CR1]\] (286); \[[@CR2]\] (26) \[[@CR3]\] (6); Systolic blood pressure in: \[[@CR4]\] (272) \[[@CR5]\], (25) \[[@CR6]\], (22); Diastolic blood pressure in: \[[@CR7]\] (269) \[[@CR8]\], (23) \[[@CR9]\], (21).

Outcome at 3 years {#Sec11}
------------------

### Absolute Risks for All Patients {#Sec12}

Surviving patients were followed-up for a minimum of 3 years and up to 3 years and 11 months. Over 3 years of follow-up, 136 died and 35 had a recurrent stroke. Table [2](#Tab2){ref-type="table"} and Figure [2](#Fig2){ref-type="fig"} shows that the 3-year cumulative risk of death was 33.4% (95% CI, 28.9 to 38.3). The risk of death was greatest in the first year after stroke (24.1%; 95% CI, 20.0 to 29.0) and particularly in the first 30 days after stroke (21.6%; 95% CI, 17.7 to 25.9). Beyond the first year, approximately 3 to 5% of survivors continued to die each year. No patient was lost to follow-up.Table 2**Kaplan-Meier estimates of probability of survival within defined time intervals after the index stroke1 day to 30 days1 to 6 months6 m to 1 year1-2 years2-3 years**Risk of death %\*21.62.94.94.83.2CI 95%(17.7-25.9)(1.4-5.4)(2.7-7.9)(2.7-7.9)(1.5-6.0)Cumulative risk, %21.624.127.831.233.4CI 95%(17.7-25.9)(20.0-29.0)(24.5-32.3)(26.7-36.0)(28.9-38.3)Number at risk407319309294280Number of deaths881015149Cumulative deaths8898113127136\*Risk of death = (1-Kaplan-Meier estimate).Figure 2Kaplan-Meier curve showing the 3-year probability of survival after a first-ever stroke derived from Joinville Stroke Register, 2009--10. Dots on either side of the solid line indicate 95% CIs; n indicates number at risk at the beginning of each year.

#### Absolute risks for subgroups {#FPar1}

As expected, stratification by the type of the first-ever stroke showed that subarachnoid hemorrhage was associated with a substantially greater number of case fatalities. The 30-day case-fatality rate was 54% (12/28) in SAH, 37% (16/43\] in HS and 12% (40/336) in IS patients. After the first month the cumulative risk of death for all stroke types decreased. Up to 3 years the cumulative risk of death was 54% (15/28) in SAH, 53% (23/43) in PIH and 27% (92/336) in IS. Figure [3](#Fig3){ref-type="fig"} compares the survival probabilities between IS, PIH and SAH.Figure 3Kaplan-Meier curve showing the 3-year probability of survival after a first-ever stroke among primary intracerebral hemorrhage (PIH), sub-arachnoid hemorrhage (SAH) and ischemic stroke (IS).

Among IS sub-types, the 30-day case-fatality was 22% (20/91) in UND, 18% (15/85) in CE, 9% (1/11) in OD, 2% (2/92) in SAO and also 2% (1/57) in LAA. Figure [4](#Fig4){ref-type="fig"} compares the survival curve among IS over 3 years (other determined data was not included). Compared to small artery occlusion, cardioembolic stroke carried a 3.6 times greater risk of death (HR 3.6, 95% CI, 2.1 to 6.4; p = 0.001) and undetermined stroke had a 3.3 times greater risk of death (HR 3.3, 95% CI 1.9 to 5.8; p = 0.001). Data are shown in supplementary Table [1](#Tab1){ref-type="table"}.Figure 4Kaplan-Meier curve showing the 3-year probability of survival after first-ever large artery atheroatherotsclerosis (LLA), cardioembolic (CE), undetermined (UND) and small artery occlusion (SAO) ischemic stroke.

Over three years we identified a cumulative risk of 9% (35/407) for stroke recurrence. Of those, 17% (6/35) died. We found no difference in stroke recurrence rates between IS subtypes (Figure [5](#Fig5){ref-type="fig"}).Figure 5Kaplan-Meier survival curve showing the probability that, given survival, a patient with a stroke will remain free of a recurrent stroke, stratified by IS subtype (other determined IS not included).

Figure [6](#Fig6){ref-type="fig"} shows the causes of death at different time intervals after a first-ever stroke onset. During the first 30 days, 90% of deaths were due to the direct neurological effects of the index stroke. Among 30-day survivors up to 3 years, 71% of subsequent deaths were due to the first-ever (64%) or a recurrent (7%) stroke, and 23% were due to other cardiovascular causes. Among 3-year survivors, 43% of subsequent deaths were due to the first-ever (14%) or a recurrent (29%) stroke, and 7% were due to other cardiovascular causes.Figure 6Histogram showing the proportion of patients dying from different causes during different time intervals from the onset of their first-ever stroke.

Discussion {#Sec13}
==========

We identified 407 first-ever stroke cases in 2009--10 in Joinville, Brazil. Over the next 3 years, the recurrence rate was 9%, with no difference in the recurrence risk among IS subtypes. As expected, the absolute risk of death was higher in the first 30 days (22%), decreasing to 3% to 5% in the following 3 years. Therefore, a sixth of patients died within 30 days and a third died within 3 years. The 30-day case-fatality rate consisted of more than a half of SAH patients, more than a third of PIH patients and 12% of IS patients. Despite the lower case-fatality rate among IS patients, the risk of death was very distinct among IS subtypes, where CE and undetermined IS had a worse prognosis than the other IS subtypes. Indeed, the 30-day case-fatality rate was 22% in undetermined IS and 18% in CE, whereas we found 9% in other determined IS cases and 2% in SAO and LAA strokes. As in other community-based studies \[[@CR19]-[@CR21]\] we also found CE and undetermined IS were the most lethal among IS subtypes. Three years after stroke onset, CE ischemic stroke patients had a 3.6 times higher risk of death, and undetermined IS patients had a 3.3 times higher risk of death than those with small artery occlusion (p \< 0.001). The 136 deaths observed in the follow-up period included all causes of death. However, most of these were caused by cardiovascular complications in the brain or in the heart. Indeed, intracranial hypertension and immobility complications from the first-ever stroke, a recurrence, or an acute myocardial infarction were responsible for 90% of deaths within 30 days, 100% of those who died within a year and 50% of those who died within 3 years.

As far as we know, there are no other stroke survival or recurrence cohort studies in a community-based setting from low or middle-income countries. Our results were similar to other cohorts, which included all major stroke types conducted between the 1980s and the 2000s in high-income countries \[[@CR8]-[@CR11],[@CR22],[@CR23]\]. For example, in a meta-analysis with 9115 survivors from 13 studies, the pooled cumulative risk of stroke recurrence was 3.1% (95% CI, 1.7-- 4.4) at 30 days, 11.1% (95% CI, 9.0 --13.3) at 1 year and 26.4% (95% CI, 20.1--32.8) at 5 years \[[@CR24]\]. At 3 years, our recurrence rate was 8.6% (95% CI, 6.1-11.7). A cohort from Oxfordshire reported that the risk of early recurrent stroke was highest in patients with LAA, a finding that supports the need for urgent carotid imaging and prompt endarterectomy \[[@CR24]\]. However, as in other studies we did not find a higher pattern of stroke recurrence among major stroke types or IS subtypes \[[@CR9],[@CR11],[@CR19],[@CR20],[@CR23]\].

In Joinville, the one-year cumulative risk of death after a first-ever stroke was 28% (95% CI, 25% -32%) and 33% (95% CI, 29% -38%) after 3 years. Compared with other cohorts which also included SAH, PIH and IS in their samples, our rates are significantly lower than in Oxfordshire, UK (1-year: 44%, 95% CI 41-48%; 3-years: 50%, 95% CI, 46% -54%) \[[@CR7]\] and in Perth, Australia (1-year: 43%, 95% CI, 38%-48%; 3-years:50%, 95% CI, 44% -54%) \[[@CR9]\]. several authors have studied prognostic factors for long-time survival rates after stroke \[[@CR10],[@CR25]\]. It is well stablished that old age and severe impairment after stroke predict poor outcomes \[[@CR24],[@CR26]\]. We have not stratified our sample by stroke severity but one explanation for our lower risk of cumulative death might be related to lower patient age. The Joinville mean age was 63 (SD 16) years old, lower than 72 (SD not specified) years old in Oxfordshire and 73 (SD 13) years old and in Perth \[[@CR7],[@CR8],[@CR12],[@CR22]\]. Therefore, the older age for first-ever onset in UK and Australia might contribute to a worse death rate in these populations, albeit the CI rates overlapped with our sample. Joinville has been using IS thrombolysis in most city hospitals since 2005 and in its stroke unit since 2000 \[[@CR26],[@CR27]\]. Of course we cannot measure with accuracy how much these interventions, coupled with new drugs for secondary prevention which became available in the last 20 years, might be related to our better results.

There are limitations to our study. First, no patient agreed to an autopsy. Despite the fact that we double-checked each cause of death by phone and by death certificate analysis, we had no autopsy data. In contrast, the Hisayama cohort did an autopsy in 82% of their sample \[[@CR28]\]. Although the proportion of cases was not specified, the Oxfordshire and Perth cohorts reported they also carried out autopsies \[[@CR7],[@CR8]\]. Second, we believe that our data on the proportion of stroke recurrence might be underdetermined because it is possible that we missed some mild strokes that were not treated in hospitals. To avoid the capture of mild cases, we have been use the third step of WHO Stepwise surveillance criteria \[[@CR14]\]. However, we believe that this strategy is inferior to the face-to-face follow-up meetings reported in Hisayama, South London, Oxfordshire, Perth, Erlangen and Melbourne studies \[[@CR7],[@CR8],[@CR10],[@CR28],[@CR29]\]. Our strengths are the novelty of this data in low and middle-income countries. Our Registry is an ongoing state-run program so we have the ability to go back and measure the trends of recurrence and mortality risk in the near future in Joinville.

Conclusion {#Sec14}
==========

Within a community-based study design, we have confirmed that our recurrence rate are similar to other population-based studies. Our cumulative risk of death is lower than other cohorts with the same inclusion criteria, which were however conducted between one and two decades ago. As with many other authors, we also found that CE and undetermined strokes have a worse prognosis than other IS subtypes. Further studies in populations with similar socioeconomic profiles need to be do done in order to compare our results and to help in planning health policies for secondary stroke prevention.
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